S&P 500   4,443.84 (-0.26%)
DOW   34,923.68 (+0.36%)
QQQ   369.57 (-1.01%)
AAPL   145.11 (-1.23%)
MSFT   293.69 (-1.89%)
FB   351.11 (-0.52%)
GOOGL   2,822.70 (-0.76%)
TSLA   794.34 (+2.58%)
AMZN   3,375.84 (-1.45%)
NVDA   215.36 (-2.47%)
BABA   148.28 (+2.21%)
NIO   36.32 (+2.66%)
CGC   14.66 (+5.39%)
GE   106.00 (+2.12%)
MU   75.15 (+1.49%)
AMD   107.20 (+1.32%)
T   27.60 (+1.73%)
F   14.27 (+3.56%)
ACB   6.35 (+6.72%)
DIS   179.18 (+1.81%)
PFE   43.83 (-0.25%)
BA   226.19 (+2.17%)
BAC   43.40 (+2.99%)
S&P 500   4,443.84 (-0.26%)
DOW   34,923.68 (+0.36%)
QQQ   369.57 (-1.01%)
AAPL   145.11 (-1.23%)
MSFT   293.69 (-1.89%)
FB   351.11 (-0.52%)
GOOGL   2,822.70 (-0.76%)
TSLA   794.34 (+2.58%)
AMZN   3,375.84 (-1.45%)
NVDA   215.36 (-2.47%)
BABA   148.28 (+2.21%)
NIO   36.32 (+2.66%)
CGC   14.66 (+5.39%)
GE   106.00 (+2.12%)
MU   75.15 (+1.49%)
AMD   107.20 (+1.32%)
T   27.60 (+1.73%)
F   14.27 (+3.56%)
ACB   6.35 (+6.72%)
DIS   179.18 (+1.81%)
PFE   43.83 (-0.25%)
BA   226.19 (+2.17%)
BAC   43.40 (+2.99%)
S&P 500   4,443.84 (-0.26%)
DOW   34,923.68 (+0.36%)
QQQ   369.57 (-1.01%)
AAPL   145.11 (-1.23%)
MSFT   293.69 (-1.89%)
FB   351.11 (-0.52%)
GOOGL   2,822.70 (-0.76%)
TSLA   794.34 (+2.58%)
AMZN   3,375.84 (-1.45%)
NVDA   215.36 (-2.47%)
BABA   148.28 (+2.21%)
NIO   36.32 (+2.66%)
CGC   14.66 (+5.39%)
GE   106.00 (+2.12%)
MU   75.15 (+1.49%)
AMD   107.20 (+1.32%)
T   27.60 (+1.73%)
F   14.27 (+3.56%)
ACB   6.35 (+6.72%)
DIS   179.18 (+1.81%)
PFE   43.83 (-0.25%)
BA   226.19 (+2.17%)
BAC   43.40 (+2.99%)
S&P 500   4,443.84 (-0.26%)
DOW   34,923.68 (+0.36%)
QQQ   369.57 (-1.01%)
AAPL   145.11 (-1.23%)
MSFT   293.69 (-1.89%)
FB   351.11 (-0.52%)
GOOGL   2,822.70 (-0.76%)
TSLA   794.34 (+2.58%)
AMZN   3,375.84 (-1.45%)
NVDA   215.36 (-2.47%)
BABA   148.28 (+2.21%)
NIO   36.32 (+2.66%)
CGC   14.66 (+5.39%)
GE   106.00 (+2.12%)
MU   75.15 (+1.49%)
AMD   107.20 (+1.32%)
T   27.60 (+1.73%)
F   14.27 (+3.56%)
ACB   6.35 (+6.72%)
DIS   179.18 (+1.81%)
PFE   43.83 (-0.25%)
BA   226.19 (+2.17%)
BAC   43.40 (+2.99%)
NASDAQ:EVOK

Evoke Pharma Stock Forecast, Price & News

$1.37
+0.02 (+1.48 %)
(As of 09/27/2021 10:55 AM ET)
Add
Compare
Today's Range
$1.37
$1.37
50-Day Range
$1.04
$1.35
52-Week Range
$0.96
$5.00
Volume22 shs
Average Volume561,520 shs
Market Capitalization$44.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
30 days | 90 days | 365 days | Advanced Chart
Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.


Evoke Pharma logo

About Evoke Pharma

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.00 out of 5 stars

Medical Sector

1226th out of 1,352 stocks

Pharmaceutical Preparations Industry

599th out of 666 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

What stocks does MarketBeat like better than Evoke Pharma?

Wall Street analysts have given Evoke Pharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Evoke Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a increase in short interest in August. As of August 31st, there was short interest totaling 653,200 shares, an increase of 42.0% from the August 15th total of 460,000 shares. Based on an average daily volume of 517,500 shares, the short-interest ratio is presently 1.3 days. Approximately 2.1% of the company's stock are short sold.
View Evoke Pharma's Short Interest
.

When is Evoke Pharma's next earnings date?

Evoke Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Evoke Pharma
.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) announced its quarterly earnings results on Thursday, August, 12th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01.
View Evoke Pharma's earnings history
.

How has Evoke Pharma's stock price been impacted by Coronavirus (COVID-19)?

Evoke Pharma's stock was trading at $1.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EVOK stock has increased by 21.6% and is now trading at $1.35.
View which stocks have been most impacted by COVID-19
.

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the following people:
  • David A. Gonyer, President, Chief Executive Officer & Director
  • Marilyn R. Carlson, Chief Medical Officer
  • Matthew J. D'Onofrio, Secretary, Treasurer, Chief Business Officer & EVP

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY).

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

Who are Evoke Pharma's major shareholders?

Evoke Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (5.26%), Vanguard Group Inc. (3.46%), Morgan Stanley (1.80%), Morgan Stanley (1.80%), Worth Venture Partners LLC (1.23%) and Geode Capital Management LLC (0.60%). Company insiders that own Evoke Pharma stock include David A Gonyer and Matthew J D'onofrio.
View institutional ownership trends for Evoke Pharma
.

Which institutional investors are selling Evoke Pharma stock?

EVOK stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Vanguard Group Inc., and Citadel Advisors LLC. Company insiders that have sold Evoke Pharma company stock in the last year include David A Gonyer, and Matthew J D'onofrio.
View insider buying and selling activity for Evoke Pharma
or view top insider-selling stocks.

Which institutional investors are buying Evoke Pharma stock?

EVOK stock was bought by a variety of institutional investors in the last quarter, including AIGH Capital Management LLC, Worth Venture Partners LLC, Sabby Management LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Evoke Pharma
or or view top insider-buying stocks.

How do I buy shares of Evoke Pharma?

Shares of EVOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $1.35.

How much money does Evoke Pharma make?

Evoke Pharma has a market capitalization of $43.79 million and generates $20,000.00 in revenue each year.

How many employees does Evoke Pharma have?

Evoke Pharma employs 5 workers across the globe.

What is Evoke Pharma's official website?

The official website for Evoke Pharma is www.evokepharma.com.

Where are Evoke Pharma's headquarters?

Evoke Pharma is headquartered at 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company can be reached via phone at (858) 345-1494 or via email at [email protected].


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.